Blog: Pharmas acquiring exclusive rights to gain access to new markets and innovation will be a strong trend in 2017

Mar 29th 2017 Author:

Michael Jewell

View Profile

In an expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, discusses why acquiring exclusive rights will continue to be a key driver for pharma mergers and acquisitions (M&A) in 2017 by providing companies with cheaper and faster access to new innovation, markets and geographies, while also enabling pharmas to unlock significant synergies allowing them to remain competitive.

Read full article in Pharma Letter here